Topic

navacaprant

A collection of 2 issues

Neumora Therapeutics Faces 80% Stock Plunge After Drug Trial Setback

Neumora Therapeutics' navacaprant fails Phase 3 trial endpoints, causing an 80% stock value drop. Discover the impact of this significant biotech setback.

Neumora Shares Plummet After Depression Drug Trial Fails

Neumora Therapeutics Inc. faces a setback as its depression drug, navacaprant, fails in a critical final-stage study, causing a sharp decline in shares.